Market Intelligence, Clinical Progress, and High-Purity Reagents for Pancreatic, Colorectal, NSCLC, and Other Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KRAS G12V drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KRAS G12V Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Intracellular expression optimized. |
View KRAS G12V Products |
| Gene Delivery | KRAS G12V Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View KRAS G12V Products |
| Benchmark Ab | Anti-KRAS G12V (Sequence of Clinical Biosimilar) Recombinant positive control for expression validation. |
View KRAS G12V Products |
| Validator | KRAS G12V siRNA Set For knockdown verification and specificity checks. |
View KRAS G12V Products |
| Related Target A | KRAS WT Crucial for selectivity counter-screening to avoid off-target toxicity. |
View KRAS WT Products |
| Related Target B | SHP2 Synergistic pathway node for combination therapy rationale. |
View SHP2 Products |
| Related Target C | SOS1 Guanine nucleotide exchange factor; key resistance bypass target. |
View SOS1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant Selectivity Counter-screening | Homolog panel proteins (WT, G12C, G12D, G12V) rigorously checked by Theoretical MW and Sequence Verification. |
| Intracellular Conformation Integrity | Recombinant mutant proteins formulated for structural stability in biophysical assays (SPR/ITC). |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as reliable positive controls. |
| False Positives in Phenotypic Screens | Validated siRNA included for precise genetic target knockdown and specificity checks. |
Live KRAS G12V R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KRAS G12V therapeutics is intensifying, with major players shifting focus from traditional covalent approaches (which succeeded in G12C) to non-covalent inhibitors, PROTACs, and TCR-T cell therapies. Because the G12V mutation lacks a reactive cysteine, traditional irreversible binding is not feasible. As first-generation KRAS(OFF) and Pan-KRAS therapies reach the clinic, the next wave of R&D is targeting the active KRAS(ON) GTP-bound state and exploring combinatorial pathway suppression to preempt adaptive resistance mechanisms.
Key Mutation Context (from Fact Payload)
The KRAS G12V mutation is one of several clinically relevant alterations in the KRAS gene. Other notable mutations include:
- NS3 mutation (dbSNP rs193929331): a variant associated with specific contexts.
- GASC mutation: found in a patient with Costello syndrome, exhibits only minor alt.
- AML-associated mutation: expression in 3T3 cells causes cellular transformation, and expression in COS cells also shows effects. These underscore the complexity of KRAS-driven malignancies and the need for selective targeting strategies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Non-Covalent) | Mirati (BMS), Revolution Medicines | Pancreatic, Colorectal Cancers | Binding Kinetics (Need high-purity mutant vs WT proteins for SPR) |
| Pan-KRAS / KRAS(ON) Inhibitors | Revolution Medicines, Novartis | Solid Tumors | Conformational Screening (Need sequence-verified structural integrity) |
| TCR-T / Neoantigen Vaccine | Kite Pharma, Elicio Therapeutics | Refractory Solid Tumors | Epitope Validation (Need precise peptide/protein standards) |
| PROTACs / Degraders | Arvinas, Biotheryx | NSCLC, PDAC | Ternary Complex Formation (Need purified intracellular protein panels) |